https://pharminent.com/amylyxs-avexitide-succeeds-in-phase-3-pivotal-study-for-post-bariatric-hypoglycemia/ 2026-08-18T19:37:49Z Pharminent en Amylyx's Avexitide Succeeds in Phase 3 Pivotal Study for Post-Bariatric Hypoglycemia 2026-08-18T19:37:49Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-18-2026/ 2026-08-18T19:06:09Z Pharminent en Strategic News Watch • August 18, 2026 2026-08-18T19:06:05Z Blog https://pharminent.com/astrazeneca-claims-dual-lung-cancer-phase-3-wins-but-bispecific-failure-steals-the-headline/ 2026-08-17T20:19:39Z Pharminent en AstraZeneca Claims Dual Lung Cancer Phase 3 Wins, but Bispecific Failure Steals the Headline 2026-08-17T20:04:00Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-17-2026/ 2026-08-17T18:17:18Z Pharminent en Strategic News Watch • August 17, 2026 2026-08-17T18:17:16Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-august-15-2026/ 2026-08-17T14:04:59Z Pharminent en Week in Review • INTELLIGENCE BRIEF • August 15, 2026 2026-08-17T14:04:56Z Blog https://pharminent.com/novo-nordisk-and-aws-form-ai-partnership-to-speed-drug-discovery/ 2026-08-18T13:56:18Z Pharminent en Novo Nordisk and AWS form AI partnership to speed drug discovery 2026-08-17T11:04:52Z Blog https://pharminent.com/sandoz-targets-industry-patent-void-with-322m-henlius-deal/ 2026-08-18T13:56:33Z Pharminent en Sandoz targets industry patent void with $322m Henlius deal 2026-08-17T10:47:38Z Blog https://pharminent.com/lantheus-holdings-alzheimers-radiodiagnostic-secures-fda-approval/ 2026-08-18T13:57:00Z Pharminent en Lantheus Holdings' Alzheimer's radiodiagnostic secures FDA approval 2026-08-17T10:47:36Z Blog